KDIGO Controversies Conference on Therapies Targeting B Cells in Immune-Mediated Kidney Diseases: Scope of Work Open for Pubic Comment Through April 21

KDIGO is holding a Controversies Conference on Therapies Targeting B Cells in Immune-Mediated Kidney Diseases. The conference will take place in Panama City, Panama, in June 2025. Jürgen Floege, MD (University of Aachen, Germany) and Brad Rovin, MD (Ohio State University, United States) will co-chair this conference.

KDIGO makes preliminary Scope of Work documents available for public review before final planning of any Controversies Conference. We invite you to share your comments on the Scope of Work via the feedback form on the conference website through Monday, April 21. Your input will help ensure that the conference addresses the most relevant and impactful topics in this rapidly advancing area.

This conference will bring together a multidisciplinary group of global experts—including nephrologists, rheumatologists, immunologists, pathologists, and others—to examine the evolving role of B cell-targeted therapies in managing autoimmune and immune-mediated kidney diseases. Discussions will explore the efficacy and safety of these therapies and consider how they may supplement or replace current treatment paradigms.

The Scope of Work outlines the key topics the conference will address, including the biological rationale for targeting B cells, current and emerging therapeutic approaches, patient selection, timing and duration of therapy, monitoring, and safety considerations. It also aims to identify knowledge gaps, research priorities, and practical strategies for integrating B cell–targeted therapies into clinical practice. The format will include plenary sessions and focused breakout discussions, with the goal of developing a KDIGO position statement to guide the global kidney community.